Management Comment "VARUBI provide sustain protection from delayed nausea and vomiting for patients who are receiving emetogenic chemotherapy. And it’s administered with the single oral dose prior to initiation of chemotherapy.Importantly, use of VARUBI does not require oncologists to adjust the dose of dexamethasone or many other medicines that a patient maybe taken during their cancer therapy since it does induce or inhibit CYP3A4."-CEO Lonnie Moulder